fbpx
Connect with us

CBD CONDITIONS & TREATMENTS

Treatment of Obesity with CBD

Published

on

It should hardly be a controversial idea that obesity is a major health problem in our society. Type II diabetes, cardiovascular disease, and hypertension are all far too common and still increasing on a per capita basis particularly in the United States.

This represents an extremely important health concern that impacts all of us, as should have been made clear throughout every step of the health care reform debate.

While we have found many different ways to help treat individuals dealing with obesity, many of the tools in that establishment toolbox have a number of unwanted side effects and pose risks of their own.

Hence, scientists and researchers are on the lookout for new ways to combat obesity.

Interestingly enough, cannabinoids have risen to the fore as one of the possibilities in that search. The point is to find ways to replace drugs that are now commonly used to treat obesity that have highly toxic side effects. Cannabidiol, or CBD, has already shown, as we will see below, to be effective in many ways in this fight. And we know that it does not have any harmful side effects.

As far as efficacy, cannabinoids have been found to have important regulatory properties. As we know, the endocannabinoid system is central to the regulation of many different functions and processes throughout the body. Included in the list of its many governance responsibilities, we find appetite, eating, and energy expenditure readily at hand.

Naturally, the stigma associated with the psychoactive effects found stemming from consumption of THC has long poisoned the medical establishment against cannabinoids for many different types of uses. However, as we have covered, CBD does not result in those same psychoactive effects. Hence, involvement of CBD in the fight against obesity is a natural fit.

Weight Control and the CB2 Receptor

Research thus far on the extent to which cannabinoids may impact the fight against obesity has generally focused on the CB1 receptor. As we have noted, this hasn’t really led to much success. The CB1 receptor is triggered in a manner that generally is involved in the same psychoactive effects that we wish to avoid.

However, CBD is not really implicated in the binding process with the CB1 receptor. This makes it an excellent candidate as we search for tools in this battle.

The Research Landscape

According to recent research, intake levels for food as well as body weight changes have been shown to be broadly affected by CBD in both mice and rats. The fact that this research already extends to two different species of mammals suggests quite strongly that the conclusions derived from these studies will also apply to human beings.

One study that was focused on a variety of different cannabinoids look at how they may work as appetite suppressants. In the study, adult male rats were given a variety of different cannabinoids – cannabigerol, cannabidiol, cannabinol or cannabinol plus a CB1 antagonist (SR141716A). They were also supplied with plenty of food.

Interestingly, after analyzing their food intake hour by hour, several changes were found based on different cannabinoids implemented. To make a long story short, CBD was the only one that was effective, and it was shown to reduce food intake over the entire experimental period.

The big point here is this: based on research on multiple different mammals, CBD has been shown to work as an appetite suppressant and counters the munchies effect driven by consumption of THC.

We aren’t exactly sure how or why this is the case, but sometimes the most important thing is simply to know that it is. Naturally, we look forward to more research and more proof. But at this point, it would appear as though CBD is headed toward being seen as a viable alternative for effective treatment in the battle against obesity.

Continue Reading
Advertisement

CBD CONDITIONS & TREATMENTS

CannTrust Holdings Inc (NYSE:CTST) Penetrates Into The United States After Investing $20 Million

Published

on

CannTrust Holdings Inc (NYSE:CTST), a Canadian company that produces and sells medical and recreational marijuana has announced the expansion of its business into the United States.

The Canadian firm revealed that it signed a Letter of Intent through which it will start working with Elk Grove Farming Company, LLC to access more than 3,000 hemp production acres in California. The two companies struck a joint partnership that will allow CannTrust to secure a footing in the California market which is one of the biggest cannabis markets in the U.S.

“This agreement represents another bold move for CannTrust. Our U.S. operation is expected to deliver a significant increase in low-cost production capacity,” stated CannTrust CEO Peter Aceto.

CannTrust is financially ready to tap into the U.S market

The CannTrust CEO also noted that the company will take advantage of its experience in the formulation of standardized CBD products as part of its strategy to enter the U.S market. Mr. Aceto also revealed that his company’s successful equity offering provided enough financial muscle to fuel its ambitious expansion plans.

CannTrust aims to be among the leading and trusted suppliers of high-quality, standardized CBD formulations derived from hemp. The company believes that there will be an increasing demand for high-grade CBD formulations from international retailers. It therefore makes sense to invest in processes that will add value to the end product such as genetic studies and expert growing practices to achieve the highest safety and quality standards.

Elk Grove and CannTrust will each have 50% ownership in their joint operations. Elk Grove is an ideal partner for the endeavor because it has years of farming experience in a variety of products. Its focus includes products designed for crop protection, supply, and input. Its operations are distributed across California, which means that the groundwork has already been laid for the partnership. It will thus be easier for the CannTrust to penetrate into the California market.

Elk Grove executive Morgan Houchin stated that his company was excited about the partnership with CannTrust. He added that his firm’s experience in farming operations will be a great combination with CannTrust’s experience in creating class-leading formulations.

Continue Reading

CBD CONDITIONS & TREATMENTS

Rocky Mountain High Brands Inc (OTCMKTS:RMHB) Strikes Broker Deal With Carlin Group

Published

on

Lifestyle brand management firm Rocky Mountain High Brands Inc (OTCMKTS:RMHB) announced on Wednesday that it secured a broker deal with Carlin Group for its products in the retail space.

The broker agreement will allow Carlin to represent RMHB’s CBD-infused drinks through the HEMPd brand. It will also represent beverages infused with Hempseed extract under RMHB brands. The deal will also cover CBD-infused wellness products such as lotions, water-soluble solutions, capsules, gummies and tinctures as part of the HEMPd brand. Spirit Water will also be covered under the agreement.

The RMHB-Carlin broker deal covers multiple states. They include Missouri, Nebraska, Texas, South Dakota, North Dakota, Minnesota, Wisconsin, Illinois, Pennsylvania, Tennessee, Kentucky, Ohio, Indiana, and Michigan.

“We are very excited about the opportunity to have our entire product line represented by Carlin Group,” stated RMHB CEO Michael Welch.

The Carlin broker deal will boost RMHB’s exposure

Welch noted that the broker deal will strategically allow RMHB to leverage optimal exposure to mass marketers, grocery store chains, convenient stores, major retailers and other types of outlets. The company would not have managed to reach such a wide range of outlets cost-effectively without a broker deal.

The RMHB CEO also added that his company and Carlin will maintain a close collaboration so that they can facilitate retail availability of RMHB products. Welch also revealed that RMHB reviewed numerous other retail introduction options. This was before settling on Carlin which the company believes is the best-suited brand to rapidly get its products onto retail shelves.

Carlin Group’s Managing Director Albert Vergilio noted in a statement that his company was excited to host RMHB and the CBD-based products that are part of its HEMPd brand in Carlin’s new CBD division. He also added that it is part of investing in the future of CBD considering the fast-tracked popularity of CBD products, and the regulations that govern them.

Carlin’s sales team will undergo some training to get them acquainted with RMBH’s products. The sales team will then hold meetings with corporate customers as part of the retail rollout of the products. Sales that will be part of the broker deal are expected to kick off in Q3.

Continue Reading

CBD CONDITIONS & TREATMENTS

Wildflower Brands Inc (OTCMKTS:WLDFF) Establishes Footprint Across The US With PO For Hemp CBD Products From Dillard’s Department Stores And Eyes Markets In Texas And Florida

Published

on

Wildflower Brands Inc (OTCMKTS:WLDFF) has announced establishing a nationwide presence with a PO from Dillard’s Department store. The company has fulfilled the PO received from Dillard.

Hemp CBD products in 292 locations

Dillard’s department store will showcase the premium hemp CBD products of Wildflower in its 292 locations across the US. With its best practices and transparency, Wildflower is eyeing the key markets in Texas and Florida. The company will educate the customers in these regions about salable products. Wildflower has received subsequent orders from Dillard’s and is fulfilling the requirements.

Chief Executive Officer of Wildflower, William Maclean said the supply of CBD infused products to Dillard’s Department stores doubles the existing retail locations in the nation. The company aims to capitalize on its brand to become a household name. It will improve loyalty building because of the reputation and respect of Dillard’s as a retailer. Wildflower aims to provide health and wellness benefits of its CBD infused products to the customers in the US through Dillard’s.

Signs a deal with Highmark Interactive

Wildflower has signed a deal to use EQ – Brain Tracking, mobile software of Highmark Interactive, in the clinical research to study the functional neurological and cognitive effects of CBD. The company aims to get meaningful results and data that help to understand the functional and cognitive neurological properties of the cannabinoids.

William said the company would collect testimonials from the customers on its products that provide the health and wellness needs using plant-based solutions. The company will strive to improve the products, and the research helps it to reach that goal and growth with continued investments.

Acquires City Cannabis Corp

Wildflower has signed an LOI on April 3, 2019, to take over City Cannabis Corp. The company will issue its 60 million common shares for the takeover. The companies will complete the acquisition on receiving advice from corporate, tax, and securities law departments.

The cannabis retailer City Cannabis holds two licenses in the City of Vancouver to market cannabis. It is generating profits through operating dispensaries in Vancouver. The acquisition helps Wildflower to expand retail footprint using the expertise of City Cannabis.

Continue Reading
Advertisement
Advertisement
Advertisement






Trending Stories